Palmitoyl Tripeptide-1

Identity and Structure

Palmitoyl tripeptide-1 (Pal-GHK) is the lipidated form of the tripeptide Gly-His-Lys — the same three-amino-acid sequence that forms the core of GHK-Cu, the naturally occurring copper-binding peptide first isolated by Loren Pickart in 1973. The palmitoyl variant pairs GHK with a 16-carbon palmitic acid chain attached at the N-terminal glycine, converting a small hydrophilic peptide into an amphipathic molecule capable of crossing the stratum corneum. Unlike GHK-Cu, palmitoyl tripeptide-1 is not complexed to copper and is not intended to deliver copper into the skin — it is marketed strictly as a collagen-signalling peptide.

The molecule was introduced commercially by Sederma in the mid-2000s as the collagen-signalling component of Matrixyl 3000, the ingredient house's best-known anti-aging peptide blend. Matrixyl 3000 pairs Pal-GHK with palmitoyl tetrapeptide-7, the rationale being that the former drives extracellular-matrix synthesis while the latter suppresses the low-grade inflammation that accelerates matrix breakdown. The two are almost always formulated together; independent use of Pal-GHK as a standalone cosmetic ingredient is comparatively rare.

Proposed Mechanism

The biological rationale for Pal-GHK rests on the well-characterized activity of native GHK on fibroblasts. GHK in its copper-bound form has been shown in vitro to upregulate collagen I and III, elastin, decorin, and glycosaminoglycans; to modulate matrix metalloproteinase (MMP) expression; and to promote fibroblast migration in wounded dermis. The Pal-GHK variant is presumed to deliver the tripeptide intact into the living epidermis, where endogenous copper ions can then complete the complex at physiologic concentrations. Whether this fully recapitulates the activity profile of pre-formed GHK-Cu is an open question — the in vitro data for Pal-GHK specifically is thinner than the GHK-Cu body of work, and most citations for its mechanism implicitly borrow from the GHK-Cu literature.

Clinical Evidence

The most-cited clinical study supporting Matrixyl 3000 — and by extension Pal-GHK — is a Sederma-sponsored trial reporting visible reductions in wrinkle depth and surface roughness over 8 to 12 weeks of twice-daily application, with effect sizes broadly comparable to those reported for Matrixyl (palmitoyl pentapeptide-4). Independent replication outside ingredient-manufacturer datasets is limited, and the clinical work rarely separates the contributions of the two constituent peptides in the blend — a methodological gap that has gone largely unaddressed in the two decades since launch.

The honest summary: there is a plausible mechanistic case and a real (if modest) clinical signal for Matrixyl 3000 as a whole. How much of that signal is attributable to Pal-GHK specifically, versus its tetrapeptide partner, versus the emollient vehicle, is not something the published literature can currently resolve.

Formulation Considerations

Effective use levels are typically in the parts-per-million range of active peptide. As with other palmitoyl peptides, Pal-GHK is stable at near-neutral pH but is vulnerable to strong acids, oxidizers, and high-temperature processing. Formulators generally avoid combining it in the same step as strong AHAs, benzoyl peroxide, or high-strength vitamin C, and aqueous serums are usually buffered to pH 5–6. Pal-GHK is also compatible with niacinamide, ceramides, and most peptide partners; it is a common resident in "peptide serum" multi-blend formulations.

Safety and Regulatory Status

Pal-GHK is a cosmetic ingredient with no drug approval or therapeutic indication. Its safety record across nearly two decades of retail use is uneventful — occasional contact sensitivity, no systemic signals, no restricted-ingredient flags in major markets. It is not orally active, not injectable in any approved context, and not on any doping-controlled list.

Bottom Line

Palmitoyl tripeptide-1 is best understood as the topical-delivery counterpart to naturally occurring GHK — a cosmetic ingredient with a reasonable mechanistic case and a supporting role in the Matrixyl 3000 anti-aging blend. It is not a substitute for retinoids or sunscreen, and it is rarely evaluated in isolation. For consumers it is a credible, well-tolerated peptide to layer into a maintenance routine, with the realistic expectation of small, cumulative improvements rather than dramatic change.